Unomedical recall of infusion sets tagged as Class I by FDA

The company notified Tandem Diabetes Care, its sole consignee, in October of the risk for infusion sets to detach from insulin pumps, disrupting insulin delivery.

By Nick Paul Taylor • Nov. 28, 2023

Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s

The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.

By Elise Reuter • Nov. 21, 2023

Abbott Diabetes Care CMO Mahmood Kazemi on expanding CGM access

Kazemi hopes anyone with diabetes will be able to access the technology, even people who don’t take insulin.

By Elise Reuter • Nov. 17, 2023

Wegovy study details revive debate over GLP-1 impact on devices

The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.

By Susan Kelly • Nov. 13, 2023

NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.

By Nick Paul Taylor • Nov. 9, 2023

Diabetes tech firms focusing on Type 2 patients

Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

By Elise Reuter • Nov. 7, 2023

5 companies to watch as medtech earnings wind down

Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

By Nick Paul Taylor • Nov. 6, 2023

Drilling down on obesity drugs: What medtech executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 2, 2023

GE HealthCare’s imaging AI will become ‘increasingly meaningful’ to growth: Moody’s

Even if modestly accretive, AI could support longer-term revenue targets at GE HealthCare and its competitors, Moody’s analysts wrote.

By Nick Paul Taylor • Oct. 27, 2023

GE HealthCare, Novo Nordisk partner to use ultrasound to treat diabetes, obesity

The collaborators will study the use of peripheral focused ultrasound as a non-invasive, non-pharmacological method of managing blood glucose.

By Nick Paul Taylor • Oct. 25, 2023

Insulet receives FDA clearance for Omnipod 5 iPhone app

The application removes the need for patients with iPhones to carry a separate controller to manage bolus dosing.

By Elise Reuter • Oct. 23, 2023

Abbott raises outlook amid strong Q3, sees momentum into 2024

Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.

By Susan Kelly • Oct. 18, 2023

Boston Scientific wins diabetic neuropathy approval, joining rivals in growing market

The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.

By Nick Paul Taylor • Oct. 12, 2023

Best Buy to sell continuous glucose monitoring systems

It’s the tech retailer’s first foray into prescription-based medical device sales.

By Rebecca Pifer • Oct. 9, 2023

Insulet CFO leaves for 3M health spinoff

Wayde McMillan is the second high-profile medtech executive in recent months to join 3M.

By Elise Reuter • Oct. 4, 2023

Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts

The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.

By Nick Paul Taylor • Sept. 29, 2023

Intarcia’s diabetes drug-device combo voted down again by FDA panel

The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.

By Gwendolyn Wu • Sept. 25, 2023

Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom

Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom. 

By Nick Paul Taylor • Sept. 25, 2023

Bigfoot CEO talks Abbott acquisition, future of diabetes tech

Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.

By Elise Reuter • Sept. 15, 2023

Insulin pump-makers grapple with questions about GLP-1s

The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.

By Elise Reuter • Sept. 14, 2023

FDA proposes 3 guidances to improve 510(k) clearance process

The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.

By Nick Paul Taylor • Sept. 7, 2023

Abbott to buy smart insulin pen cap maker Bigfoot

The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.

By Elise Reuter • Sept. 6, 2023

Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google

The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”

By Nick Paul Taylor • Sept. 5, 2023

Beta Bionics raises $100M to challenge Medtronic, Tandem for automated insulin dosing market

The company’s iLet Bionic Pancreas automates insulin dosing without requiring mealtime carb counting. 

By Nick Paul Taylor • Sept. 1, 2023

Why medtech firms are putting diabetes tech in consumer devices

As Abbott develops a line of wearable wellness devices, and Dexcom makes a CGM for people with diabetes who don’t take insulin, both companies are turning to new users for future growth.

By Elise Reuter • Updated Aug. 31, 2023